AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

This acquisition will give AbbVie acces to Celsius Therapeutics’ lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.